These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21117034)

  • 1. Halofuginone and muscular dystrophy.
    Pines M; Halevy O
    Histol Histopathol; 2011 Jan; 26(1):135-46. PubMed ID: 21117034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxy group requirement for halofuginone-dependent inhibition of muscle fibrosis and improvement of histopathology in the mdx mouse model for Duchenne muscular dystrophy.
    Wellner G; Mordechay S; Evans P; Genin O; Pines M; Halevy O
    Histol Histopathol; 2019 Jul; 34(7):791-801. PubMed ID: 30628720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
    Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
    Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion.
    Roffe S; Hagai Y; Pines M; Halevy O
    Exp Cell Res; 2010 Apr; 316(6):1061-9. PubMed ID: 20060825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
    Halevy O; Genin O; Barzilai-Tutsch H; Pima Y; Levi O; Moshe I; Pines M
    Histol Histopathol; 2013 Feb; 28(2):211-26. PubMed ID: 23275304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.
    Nevo Y; Halevy O; Genin O; Moshe I; Turgeman T; Harel M; Biton E; Reif S; Pines M
    Muscle Nerve; 2010 Aug; 42(2):218-29. PubMed ID: 20589893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
    Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
    Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Halofuginone promotes satellite cell activation and survival in muscular dystrophies.
    Barzilai-Tutsch H; Bodanovsky A; Maimon H; Pines M; Halevy O
    Biochim Biophys Acta; 2016 Jan; 1862(1):1-11. PubMed ID: 26454207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Halofuginone improves muscle-cell survival in muscular dystrophies.
    Bodanovsky A; Guttman N; Barzilai-Tutsch H; Genin O; Levy O; Pines M; Halevy O
    Biochim Biophys Acta; 2014 Jul; 1843(7):1339-47. PubMed ID: 24703880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling.
    Gnainsky Y; Kushnirsky Z; Bilu G; Hagai Y; Genina O; Volpin H; Bruck R; Spira G; Nagler A; Kawada N; Yoshizato K; Reinhardt DP; Libermann TA; Pines M
    Cell Tissue Res; 2007 Apr; 328(1):153-66. PubMed ID: 17180598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.
    Cofre C; Acuña MJ; Contreras O; Morales MG; Riquelme C; Cabello-Verrugio C; Brandan E
    Biofactors; 2015; 41(2):111-20. PubMed ID: 25809912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy.
    Mordechay S; Smullen S; Evans P; Genin O; Pines M; Halevy O
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
    McGaha TL; Phelps RG; Spiera H; Bona C
    J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone.
    Huebner KD; Jassal DS; Halevy O; Pines M; Anderson JE
    Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1550-61. PubMed ID: 18263710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Expression of Moesin in Muscular Dystrophies.
    Pines M; Levi O; Genin O; Lavy A; Angelini C; Allamand V; Halevy O
    Am J Pathol; 2017 Mar; 187(3):654-664. PubMed ID: 28082118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice.
    Barzilai-Tutsch H; Dewulf M; Lamaze C; Butler Browne G; Pines M; Halevy O
    Hum Mol Genet; 2018 Aug; 27(16):2817-2829. PubMed ID: 29771357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of halofuginone in fibrosis: more to be explored?
    Luo Y; Xie X; Luo D; Wang Y; Gao Y
    J Leukoc Biol; 2017 Dec; 102(6):1333-1345. PubMed ID: 28986385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The involvement of collagen triple helix repeat containing 1 in muscular dystrophies.
    Spector I; Zilberstein Y; Lavy A; Genin O; Barzilai-Tutsch H; Bodanovsky A; Halevy O; Pines M
    Am J Pathol; 2013 Mar; 182(3):905-16. PubMed ID: 23274062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy.
    McLoon LK
    Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1505-7. PubMed ID: 18310507
    [No Abstract]   [Full Text] [Related]  

  • 20. Muscle Weakness and Fibrosis Due to Cell Autonomous and Non-cell Autonomous Events in Collagen VI Deficient Congenital Muscular Dystrophy.
    Noguchi S; Ogawa M; Malicdan MC; Nonaka I; Nishino I
    EBioMedicine; 2017 Feb; 15():193-202. PubMed ID: 28043812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.